LTR Pharma has been featured in The Australian, for our innovative breakthrough in men’s health – erectile dysfunction nasal spray, Spontan. In the article, non-exective director Dr. Julian Chick highlights the essence of Spontan, emphasising its simple proposition – speed and spontaneity. “As the name suggests, the main factor is this is a product that […]
Australian Associated Press journalist Derek Rose has shared LTR Pharma’s story following the launch of our IPO last week. Of the Company’s commercialisation plans, he wrote: “Because the drug is already approved in a different form, LTR should have an easier time bringing SPONTAN® to market than companies seeking approval of an all-new medicine…SPONTAN® could […]
LTR Pharma has been featured in Biotech Daily. The article discusses the potential for the Company to disrupt the Erectile Dysfunction (ED) market with its commercialisation plans for intra-nasal product, SPONTAN®. The article also showcases the expertise of the team at LTR Pharma, writing: “The company said its Mr Rodne was the former chief executive […]
LTR Pharma Executive Chairman, Lee Rodne, speaks to OnMarket about the Company’s Initial Public Offer (IPO) for a proposed listing on the Australian Securities Exchange (ASX) under ticker code $LTP, and commercialisation plans for SPONTAN®, an innovative intranasal spray treatment for Erectile Dysfunction (ED).
Australian Innovators Pursue $3.6Bn Erectile Dysfunction (ED) Market Brisbane-based LTR Pharma has today secured Ethics Approval for a bio-equivalence1 clinical study of its intranasal spray for erectile dysfunction (ED), ‘SPONTAN™’ – a crucial step in fast-tracking approval for this world-first product with the U.S. Food and Drug Administration (FDA). SPONTAN’s unique delivery technology (‘Intranasal’) bypasses […]